$PCVX

Wassil Jim sold $96K of PCVX

Wassil Jim (CHIEF OPERATING OFFICER) sold 1,949 shares of Vaxcyte, Inc. (PCVX) at $49.40 on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Wassil Jim
Published Jun 3, 2026, 8:59 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 3, 2026, 9:02 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PCVX
Neutral
medium confidence
Mentioned
$PCVX
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PCVXNeutralLow
01

Why it matters

The disclosure can modestly influence short-term sentiment, but it is not a fundamental update by itself.

02

Market read

Traders may monitor for follow-on insider activity, but this specific filing is unlikely to drive a durable repricing without additional catalysts.

03

What to watch

The article provides only the sale size and plan status, not whether other insiders/funds changed positions around the same time.

Relevance 6/10Novelty 3/10Timing: SEC Form 4 filed June 3, covering a June 1 sale.

Background

SEC Form 4 reports insider transactions; 10b5-1 plans are pre-arranged to reduce timing-based trading concerns.

Company-level read

Ticker impact

$PCVXNeutralMedium confidence
Context

Vaxcyte COO Wassil Jim sold $96.3K of PCVX shares via an open-market transaction under a pre-arranged 10b5-1 plan.

Expected impact

Limited immediate impact expected; any reaction is likely sentiment-driven and short-lived.

Evidence & confidence

The filing is a routine officer sale under a pre-arranged 10b5-1 plan, with no accompanying operational/financial catalyst in the article.

Market effects

Minimal; this is company-specific insider disclosure with no stated sector/regulatory catalyst.

None.

None.

Counterpoint

Because the sale is under a 10b5-1 plan, the market may overreact; the disclosure may not reflect new bearish information.

Key entities

  • Vaxcyte, Inc.

    Subject of the insider transaction disclosure (PCVX).

  • Wassil Jim

    Chief Operating Officer who sold 1,949 shares on June 1 under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$PCVXMed

The Next Year Will Define Vaxcyte’s (PCVX) Vaccine Gamble

Vaxcyte (PCVX) reported a near-doubled net loss of $284.3M in Q2, with key Phase 3 trial results for its pneumococcal vaccine candidate VAX-31 expected by late 2026. The company has $2.5B in cash and added vaccine industry veterans to its board. Success hinges on upcoming clinical data.

$PCVXMed

Vaxcyte, Inc. (PCVX): Results of Operations and Financial Condition

Vaxcyte, Inc. (PCVX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update Topline Safety, Tolerability and Immunogenicity Data from VAX-31 Adult Phase 3 OPUS-1 Trial Expected in Fourth Quarter of 2026; OPUS-2 and OPUS-3 Phase 3 Results Expected in First Half